|
|
|
| Diagnostic values of miR-21 and miR-423-5p in patients with valvular heart disease and heart failure |
| LI Yumei1 SHENG Hongbin2 XU Hengshi1 |
1.Department of Blood Transfusion, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 201999, China;
2.Department of Clinical Pharmacy, Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine， Shanghai 201999, China |
|
|
|
Abstract Objective To investigate the potential diagnostic value of serum miR-21 and miR-423-5p for heart failure (HF) due to heart valve disease (VHD). Methods From August 2014 to April 2016, in Shanghai Ninth People′s Hospital, Shanghai Jiao Tong University School of Medicine, 60 VHD patients with HF were selected as VHD group, at the same period, 60 healthy persons were selected as control group. The levels of serum miR-21 and miR-423-5p were measured by qRT-PCR. The ROC curve was used analyse the clinical Value of miR-21 and miR-423-5p as VHD with biomarkers for diagnosis and prognosis of heart failure. Results The levels of miR-21 and miR-423-5p in sera of patients in VHD group were higher than control group, the differences were statistically significant (P < 0.05). The levels of miR-423-5p in sera of VHD patients with pulmonary hypertension (PH) were higher than VHD patients without PH, the differences were statistically significant (P < 0.05). ROC curve result showed that serum miR-21 and miR-423-5p had potential diagnostic values on HF due to VHD. Conclusion Serum miR-21 and miR-423-5p show potential diagnostic values on HF due to VHD. Moreover, serum miR-423-5p can be an effective biomarker for diagnosing VHD patients with PH.
|
|
|
|
|
|
[1] Rogers C，Bush N. Heart failure：pathophysiology，diagnosis，medical treatment guidelines，and nursing management [J]. Nurs Clin North Am，2015，50（4）：787-799.
[2] Don-Wauchope AC，McKelvie RS. Evidence based application of BNP/NT-proBNP testing in heart failure [J]. Clin Biochem，2015，48（4-5）：236-246.
[3] Omar HR，Guglin M. A single BNP measurement in acute heart failure does not reflect the degree of congestion [J]. J Crit Care，2016，33：262-265.
[4] Murach KA，McCarthy JJ. MicroRNAs，heart failure，and aging：potential interactions with skeletal muscle [J]. Heart Fail Rev，2017，22（2）：209-218.
[5] Souza RW，Fernandez GJ，Cunha JP，et al. Regulation of cardiac microRNAs induced by aerobic exercise training during heart failure [J]. Am J Physiol Heart Circ Physiol，2015，309（10）：H1629-1641.
[6] Vegter EL，Peter VDM，De Windt LJ，et al. MicroRNAs in heart failure：from biomarker to target for therapy [J]. Eur J Heart Fail，2016，18（5）：457-468.
[7] Hulanicka M，Garncarz M，Parzeniecka-Jaworska M，et al. Plasma miRNAs as potential biomarkers of chronic degenerative valvular disease in Dachshunds [J]. BMC Vet Res，2014，10（1）：205.
[8] Thome JG，Mendoza MR，Cheuiche AV，et al. Circulating microRNAs in obese and lean heart failure patients：A case-control study with computational target prediction analysis [J]. Gene，2015，574（1）：1-10.
[9] Bjork JB，Alton KK，Georgiopoulou VV，et al. Defining Advanced Heart Failure：A Systematic Review of Criteria Used in Clinical Trials [J]. J Card Fail，2016，22（7）：569-577.
[10] Simonneau G，Gatzoulis MA，Adatia I，et al. Updated clinical classification of pulmonary hypertension [J]. J Am Coll Cardiol 2013，62（25 Suppl）：D34-D41.
[11] Livak KJ，Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2-△△CT Method [J]. Methods，2001，25（4）：402-408.
[12] Brown JN，Brewer HM，Nicora CD，et al. Protein and microRNA biomarkers from lavage，urine，and serum in military personnel evaluated for dyspnea [J]. BMC Med Genomics，2014，7：58.
[13] Oliveiracarvalho V，Silva MMFD，Guimar?觔es GV，et al. MicroRNAs：new players in heart failure [J]. Mol Biol Rep，2013，40（3）：2663-2670.
[14] Min PK，Chan SY. The biology of circulating microRNAs in cardiovascular disease [J]. Eur J Clin Invest，2015，45（8）：860-874.
[15] Dong S，Ma W，Hao B，et al. microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2 [J]. Int J Clin Exp Pathol，2014，7（2）：565-574.
[16] Kolpa HJ，Peal DS，Lynch SN，et al. miR-21 represses Pdcd4 during cardiac valvulogenesis [J]. Development，2013， 140（10）：2172-2180.
[17] Gundara JS，Zhao J，Gill AJ，et al. Noncoding RNA blockade of autophagy is therapeutic in medullary thyroid cancer [J]. Cancer Med，2015，4（2）：174-182.
[18] Breitling S，Ravindran K，Goldenberg NM，et al. The pathophysiology of pulmonary hypertension in left heart disease [J]. Am J Physiol Lung Cell Mol Physiol，2015，309（9）：L924-941.
[19] Malhotra R，Dhakal BP，Eisman AS，et al. Pulmonary vascular distensibility predicts pulmonary hypertension severity，exercise capacity，and survival in heart failure [J]. Circ Heart Fail，2016，9（6）：e003-011.
[20] Wei C，Li L，Kim IK，et al. NF-kappaB mediated miR-21 regulation in cardiomyocytes apoptosis under oxidative stress [J]. Free Radic Res，2014，48（3）：282-291. |
|
|
|
